Publikace
- Prognostic role of serum C-reactive protein in patients with advanced-stage NSCLC treated with pemetrexed2017 | 1. lékařská fakulta, Lékařská fakulta v Plzni
- Pemetrexed Versus Erlotinib in the Second-line Treatment of Patients with Advanced-stage Non-squamous NSCLC Harboring Wild-type EGFR Gene2016 | Lékařská fakulta v Plzni, Přírodovědecká fakulta
- Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy2016 | 1. lékařská fakulta, Lékařská fakulta v Plzni
- The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy2016 | Lékařská fakulta v Plzni
- Sequential Treatment of Advanced-stage Lung Adenocarcinoma Harboring Wild-type EGFR Gene: Second-line Pemetrexed Followed by Third-line Erlotinib versus the Reverse Sequence2013 | Lékařská fakulta v Plzni
- Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?2024 | Lékařská fakulta v Plzni
- Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate2024 | Lékařská fakulta v Plzni
- Pembrolizumab plus enfortumab vedotin in urothelial cancer2024 | Lékařská fakulta v Plzni
- Klinická onkologie2023 | 1. léka řská fakulta, Lékařská fakulta v Plzni, 3. lékařská fakulta, 2. lékařská fakulta
- Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC2023 | Lékařská fakulta v Plzni, Ústřední knihovna, Přírodovědecká fakulta
Loading network view...